Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Phillips 66 (PSX) Price & Performance

CVS Health CorpTrade
Phillips 66Trade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Phillips 66 — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Phillips 66 trades at $281.02 (market cap $108.38B). The key difference: CVS Health Corp and Phillips 66 are close in size by market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Phillips 66 for 62 Days on average.

CVSPSX
Market Cap
$112.49B$108.38B
Volume
8,467,3921,841,742
Sector
HealthEnergy
52-Week High
$110.60$281.60
52-Week Low
$70.08$126.76
Typical Hold Time
83 Days62 Days
Enterprise Value
$174.83B$124.85B
Dividend Yield
3.02%1.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.

CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.

Phillips 66

PSX trades at $281.60, up 4.38% today, near its 52-week high. The stock shows bullish technical momentum with strong moving average support. Fundamentally, the company has beaten earnings estimates for three consecutive quarters, with a P/E of 15.5 and robust ROE of 24.02%. Recent news highlights structural strength in refining margins and AI-driven operational improvements.

Outlook remains positive with analyst consensus at Buy (57% of ratings) and a $279 price target. Key opportunities include sustained refining profitability and debt reduction. Risks involve volatile energy markets and potential policy impacts on diesel exports. Cash flow is projected to rebound to $3.0B in 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

PSX
16% Buy84% Sell
Avg holding period · 62 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Phillips 66

Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.

Read more on PSX →